| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24032 |
| Drug |
Amivantamab |
| Brand |
Rybrevant® |
| Indication |
Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion |
| Rapid review commissioned |
31/07/2024 |
| Rapid review completed |
30/09/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/10/2024 |
| Pre-submission consultation with Applicant |
03/12/2024 |
| Full submission received from Applicant |
25/04/2025 |
| Preliminary review sent to Applicant |
14/10/2025 |
